Promoted Content
Promoted Content

Find Oncology Drugs in Phase I Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APL-1501

            Therapeutic Area: Oncology Product Name: APL-1501

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Australian regulatory authorities have approved company's Phase I clinical trial of APL-1501. APL-1202 is being developed as a new drug of Asieris for the treatment of non-muscle invasive bladder cancer (NMIBC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GC012F

            Therapeutic Area: Oncology Product Name: GC012F

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: OrbiMed

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing October 28, 2020

            Details:

            Gracell’s lead FasTCAR autologous product candidate, GC012F, is being studied in an ongoing investigator-initiated Phase 1 trial in China for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its lead TruUCAR allogeneic product candidate.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lemzoparlimab,Pembrolizumab,Rituximab

            Therapeutic Area: Oncology Product Name: TJC4

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 15, 2020

            Details:

            Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APG-115

            Therapeutic Area: Oncology Product Name: APG-115

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            Ascentage Pharma's APG-115 is a selective, small-molecule inhibitor of MDM2. is the first MDM2-p53 inhibitor entering clinical development in China and APG-1252 is novel drug that restores apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins simultaneously.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CNCT19

            Therapeutic Area: Oncology Product Name: CNCT19

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: CASI Pharmaceuticals

            Deal Size: $10.4 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 29, 2020

            Details:

            With the restructuring in place, Juventas now can attract new capital to help fund its upcoming trials and build out a world-class GMP manufacturing facility for commercial production of CNCT19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): D-0502

            Therapeutic Area: Oncology Product Name: D-0502

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: GL Ventures

            Deal Size: $147.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing September 28, 2020

            Details:

            D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen receptor antagonist, with therapeutic potential for the treatment of hormone receptor positive breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TAEST16001

            Therapeutic Area: Oncology Product Name: TAEST16001

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: GenScript Biotech Corporation

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 24, 2020

            Details:

            As the first product in XLifeSc's pipeline, TAEST16001 enables autologous T-cell transduced with a replication incompetent lentiviral vector to express NY-ESO-1-specific TCR.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): oHSV-1

            Therapeutic Area: Oncology Product Name: MVR-T3011

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shanghai Healthcare Capital

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing September 23, 2020

            Details:

            This investment further deepens ImmVira's collaboration in the MVR-T3011 intratumoral program and highlights the commitment from the parties to the program's commercial success.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lemzoparlimab

            Therapeutic Area: Oncology Product Name: TJC4

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 21, 2020

            Details:

            Lemzoparlimab is a highly differentiated anti-CD47 monoclonal antibody originally discovered and developed by I-Mab. It is designed to minimize inherent binding to normal red blood cells while preserving its strong anti-tumor activity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ZN-A-1041

            Therapeutic Area: Oncology Product Name: ZN-A-1041

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            ZN-A-1041 is being developed to address the unmet medical need associated with brain metastases accompanying HER2+ advanced breast cancer.

            PharmaCompass